Longevity biotech is all the rage in Silicon Valley for human health. And now there’s a clinical trial with a new twist: longevity science for dogs.
What’s happening:
- Silicon Valley based startup Loyal is launching a clinical trial to validate their therapeutic drug for extending dog’s lifespan
- The new clinical trial is widely seen as the largest clinical trial ever for veterinary medicine
- Loyal has notable backers such as Khosla Ventures, First Round Capital, Box Group, Collaborative Fund, The Longevity Fund and others
Why it matters:
- There have been very few meaningful breakthroughs in the science around helping animals live longer and extend lifespan
- If Loyal is able to successful win FDA approval they would become the first ever startup to have a prescription medication for extending dog’s lifespan and overall quality of mobility and health
By the numbers:
- Over 1,000 dogs will receive the drug manufactured by Loyal, which will be disguised inside of a treat
The intrigue:
- Loyal is keeping the specifics around their drug and how it works a closely guarded secret until the completion of the clinical trial
Going deeper:
- If the clinical trial proves successful Loyal believes it could have major implications for the health of human beings as well
